Supplementary Figure 3 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
crossref(2023)
摘要
Supplementary Figure 3
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
crossref(2023)
Supplementary Figure 3